[18F]-FDG positron imaging in clinical management of lymphoma patients

Critical Reviews in Oncology/Hematology

Volumn 38, Issue 3, 2001, Pages 193-221

  Talbot, J N ^a,b   Haioun, C ^a,c   Rain, J D ^a,d   Meignan, M ^a,c   Wioland, M ^e   Misset, J L ^a,f   Grahek, D ^b   Kerrou, K ^b   Montravers, F ^b  

^a Lymphoma Working Party Assit P   (France)

^b HÔPITAL TENON   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e ARMAND TROUSSEAU HOSPITAL   (France)

^f HÔPITAL PAUL BROUSSE   (France)

Author keywords

18F Fluoro deoxy glucose; Children; Follow up of chemotherapy; Lymphoma; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 67;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN INJURY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHILDHOOD CANCER; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FOLLOW UP; HISTOLOGY; HUMAN; IMAGING; LYMPHOMA; MINIMAL RESIDUAL DISEASE; OPPORTUNISTIC INFECTION; POSITRON; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; REMISSION; REVIEW; SCINTIGRAPHY; SCINTILLATION CAMERA; TUMOR BIOPSY;

DISEASE MANAGEMENT; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; NEOPLASM STAGING; PROGNOSIS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035032706     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00127-5     Document Type: Review

References (61)

1. Römer W.R., Schwaiger M. Positron emission tomography in diagnosis and therapy monitoring of patients with lymphoma. Clin. Pos. Imag. 1:1998;101-110.
2. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J. Nucl. Med. 28:1987;288-292.
3. Coleman R.E., Tesar R.D. A perspective on clinical PET imaging. Clin. Pos. Imag. 2:1999;297-299.
4. Hoffman J.M., Waskin H.A., Schifter T., et al. FDG PET in differentiating lymphoma from non malignant central nervous system lesion in patients with AIDS. J. Nucl. Med. 34 :1993;567-575.
5. Villringer K., Jäger H., Dichgans M., et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J. Comput. Assist. Tomogr. 19 :1995;532-536.
6. O'Doherty M.J., Barrington S.F., Campbell M., et al. PET scanning and the human immunodeficiency virus-positive patient. J. Nucl. Med. 38 :1997;1575-1583.
7. Santiago J.F., Jana S., Glibert H.M., et al. Role of fluorine-18-fluorodeoxyglucose in the work-up of febrile AIDS patients: experience with dual head coincidence imaging. Clin. Pos. Imag. 2:1999;301-309.
8. Leskinen-Kallio S.L., Ruotsalainen U., Nägren K., et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J. Nucl. Med. 32 :1991;1211-1218.
9. Okada J., Yoshikawa K., Imazeki K., et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J. Nucl. Med. 32 :1991;686-691.
10. Okada J., Yoshikawa K., Itami M., et al. Positron emission tomography using fluorine 18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J. Nucl. Med. 33 :1992;325-329.
11. Okada J., Oonishi H., Yoshikawa K., et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann. Nucl. Med. 8:1994;187-191.
12. Newman J.S., Francis I.R., Kaminski K., et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology. 190:1994;111-116.
13. Lapela M., Leskinen S., Minn H.R., et al. Increased glucose metabolism in untreated non Hodgkin lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood. 86:1995;3522-3527.
14. Rodriguez M., Rehn S., Ahlstöm H., et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J. Nucl. Med. 36 :1995;1790-1796.
15. Dittmann H., Dohmen B.M., Soekler M., et al. Therapeutic relevance of FDG-PET in untreated Hodgkin's disease and high-grade non-Hodgkin lymphoma. J. Nucl. Med. 41:(Suppl. 5):2000;71. abstract n°278.
16. Martinez-Lazaro R., Cortès-Blanco A., Zhuang H.M., et al. Whole-body FDG-PET imaging for assessment of tumor grade of non-Hodgkin's lymphoma and Hodgkin's disease. J. Nucl. Med. 41:(Suppl. 5):2000;279. abstract n°1221.
17. Martinez-Lazaro R., Cortès-Blanco A., Zhuang H.M., et al. Diagnostic performance of whole-body FDG-PET and CT imaging in malignant lymphomas. J. Nucl. Med. 41:(Suppl. 5):2000;277. abstract n°1213.
18. Valk P.E., Pounds T.R., Wolkov H.B., et al. PET-FDG whole-body imaging in staging Hodgkin's disease: comparison to conventional imaging. J. Nucl. Med. 36:1995;199. abstract 898.
19. Hoh C.K., Glaspy J., Rosen P., et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J. Nucl. Med. 38:1997;343-348.
20. Moog F., Bangerter M., Diederichs C.G., et al. Lymphoma: role of whole-body 2-deoxy-2-[F18] fluoro-D-glucose PET in nodal staging. Radiology. 203:1997;795-800.
21. Moog F., Bangerter M., Diederichs C., et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 206:1998;475-481.
22. Moog F., Bangerter M., Kotzerke J., et al. 18-F-Fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J. Clin. Oncol. 16:1998;603-609.
23. Carr R., Barrington S.F., Madan B., et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 91:1998;3340-3346.
24. Moog F., Kotzerke J., Reske S.N. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J. Nucl. Med. 40:1999;1407-1413.
25. Bangerter M., Kotzerke J., Griesshammer M., et al. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol. 38:1999;799-804.
26. 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl. Med. Commun. 20:1999;13-20.
27. Kotzerke J., Guhlmann A., Moog F., et al. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur. J. Nucl. Med. 26:1999;31-38.
28. 18F-Fluorodeoxyglucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. J. Nucl. Med. 41:(Suppl. 5):2000;275. abstract number 1207.
29. Yap C.S., Valk P., Ariannejad M., et al. FDG-PET influences the clinical management of lymphoma patients. J. Nucl. Med. 41:(Suppl. 5):2000;70. abstract number 277.
30. 18FFDG coincidence detection PET (CoDe-PET). J. Nucl. Med. 41:(Suppl. 5):2000;278. abstract number 1217.
31. Kostakoglu L., Leonard J.P., Coleman M., et al. Evaluation of FDG-PET in the detection of bone marrow involvement in lymphoma. J. Nucl. Med. 41:(Suppl. 5):2000;71. abstract number 279.
32. Kostakoglu L., Leonard J.P., Coleman M., et al. Comparison of FDG-PET and 67GA SPECT in the staging of lymphoma. J. Nucl. Med. 41:(Suppl. 5):2000;118. abstract number 466.
33. 67Ga scintigraphy. J. Nucl. Med. 41:(Suppl. 5):2000;118. abstract number 467.
34. Hoeskstra O.S., Ossenkoppele G.J., Golding R., et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J. Nucl. Med. 34:1993;1706-1710.
35. Dimitrakopoulou-Strauss A., Strauss L.G., Goldschmidt H., et al. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur. J. Nucl. Med. 22:1995;434-442.
36. Römer W., Hanauske A.R., Ziegler S., et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 91:1998;4464-4471.
37. 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl. Med. Commun. 19:1998;1055-1063.
38. Zinzani P.L., Magnagnoli M., Chierichetti F., et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann. Oncol. 10:1999;1181-1184.
39. 131I-anti-B1 radioimmunotherapy: evaluation with FDG-PET. J. Nucl. Med. 41:2000;999-1005.
40. 18F-Fluorodeoxyglucose imaging with positron emission tomography in the follow-up of patients with lymphoma. J. Nucl. Med. 41:(Suppl. 5):2000;70. abstract number 276.
41. Spaepen K., Stroobants S., Dupont P., et al. Positron emission tomography with fluorodeoxyglucose after first line chemotherapy in non Hodgkin's lymphoma. J. Nucl. Med. 41:(Suppl. 5):2000;70. abstract number 275.
42. Torizuka T., Nobezawa S., Kobayashi M., et al. Value of FDG-PET for management of agressive malignant lymphoma in high-dose chemotherapy with transplantation. J. Nucl. Med. 41:(Suppl. 5):2000;276. abstract number 1209.
43. 67Ga scintigraphy as a prognostic tool early during chemotherapy for non-Hodgkin's lymphoma (NHL). J. Nucl. Med. 41:(Suppl. 5):2000;278. abstract number 1216.
44. 18F-FDG PET as predictor for disease free survival in Hodgkin's lymphoma. J. Nucl. Med. 41:(Suppl. 5):2000;275. abstract number 1205.
45. Hollinger E.F., Alibazoglu H., Ali A., et al. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin. Nucl. Med. 23:1998;93-98.
46. Larson S.M., Erdi Y., Akhurst T., et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET imaging: the visual response score and the change in total lesion glycolysis. Clin. Pos. Imag. 2:1999;159-171.
47. Kim E.E., Garcia J.R., Wong F.C.L., et al. Differentiation of bone lymphoma from post-treatment changes using PET with F-18 FDG. J. Nucl. Med. 35:1994;35. abstract n°132.
48. De Wit M., Bumann D., Beyer W., et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann. Oncol. 8:1997;57-60.
49. Stumpe K.D.M., Urbinelli M., Steinert H.C., et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur. J. Nucl. Med. 25:1998;721-728.
50. Garcia-Velloso M.J., Gorosquieta A., Perez-Equiza C., et al. PET-FDG versus CT in the staging and detection of relapse in patients with Hodgkin's disease or non-Hodgkin lymphoma. Two years experience. Eur. J. Nucl. Med. 25:1998;1029. abstract number PS 181.
51. Lauer I., Meller B., Baehre M., et al. Staging and radiotherapy follow-up of malignant lymphoma with PET using a coincidence gamma camera. Eur. J. Nucl. Med. 25:1998;1030. abstract number PS 185.
52. 18F-Fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 94:1999;429-433.
53. 18FDG-PET in patients with relapsed non-Hodgkin's lymphoma. J. Nucl. Med. 41:(Suppl. 5):2000;276. abstract number 1210.
54. Kropp J., Naumann R., Schirmer L., et al. Comparison of dedicated PET with hybrid PET in patients with malignant lymphomas. J. Nucl. Med. 41:(Suppl. 5):2000;71. abstract number 280.
55. Lauer I., Haase A., Prueter I., et al. Reliability of PET with gamma camera coincidence imaging versus CT/MRI in detecting remission or non-remission in malignant lymphoma. J. Nucl. Med. 41:(Suppl. 5):2000;278. abstract number 1219.
56. 18FDG coincidence imaging in the evaluation of lymphoma. J. Nucl. Med. 41:(Suppl. 5):2000;141. abstract number 557.
57. Shulkin B.L., Mitchell D.S., Ungar D.R., et al. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology. 194:1995;495-500.
58. 67Ga. J. Nucl. Med. 41:(Suppl. 5):2000;96. abstract number 380.
59. Weinblatt M.E., Zanzi I., Belakhlef A., et al. False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J. Nucl. Med. 38:1997;888-890.
60. 11C]-acetate and FDG in lymphoma. J. Nucl. Med. 41:(Suppl. 5):2000;276. abstract number 1211.
61. 18F]-fluoro-2-désoxyglucose: revue de la littérature et de nos résultats dans les cancers extrapulmonaires. Méd. Nucl. 23:(3):1999;151-168.